Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease

被引:157
|
作者
Drozdzik, M
Bialecka, M
Mysliwiec, K
Honczarenko, K
Stankiewicz, J
Sych, Z
机构
[1] Pomeranian Med Univ, Dept Pharmacol, PL-70111 Szczecin, Poland
[2] Pomeranian Med Univ, Dept Neurol, Szczecin, Poland
[3] Pomeranian Med Univ, Dept Hyg & Epidemiol, Szczecin, Poland
[4] Cty Hosp, Dept Neurol, Szczecin, Poland
来源
PHARMACOGENETICS | 2003年 / 13卷 / 05期
关键词
P-glycoprotein; MDR1; polymorphism; Parkinson's disease;
D O I
10.1097/01.fpc.0000054087.48725.dg
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
P-glycoprotein is a membrane protein encoded by the MDR1 gene, which demonstrates functional polymorphism. It is present in endothelial cells of the blood-brain barrier, thus limiting accumulation of its substrates in the central nervous system. Many epidemiological studies suggest an association between pesticides, which are substrates for P-glycoprotein, and Parkinson's disease. It was hypothesized that polymorphism of the MDR1 gene could modulate interindividual susceptibility for the disease in subjects exposed to pesticides. In a pilot case-control study involving 107 Parkinson's disease patients (30 early onset and 77 late onset patients; 59 exposed to pesticides and 48 non-exposed) and 103 controls, C3435T polymorphism of the gene was analysed. No statistically significant correlation between MDR1 gene polymorphism and Parkinson's disease was found. The 3435TT genotype was noted more frequently, but not significantly, in patients with early onset compared to late onset disease (23.3% versus 10.4%, respectively). A significant association between patients with parkinsonism exposed to pesticides and C3435T polymorphism of the MDR1 gene was found. Comparing the exposed and non-exposed patients, a statistically higher frequency of heterozygous subjects was observed (72.9% versus 47.9%, respectively). This genotype was associated with a significant, almost three-fold increased risk of disease. Similarly, a higher frequency of 3435TT subjects was revealed in exposed subjects (15.5%) compared to non-exposed patients (12.5%). In exposed versus non-exposed subjects, patients carrying at least one 3435T allele (i.e. homozygous and heterozygous) had a significant, five-fold higher risk of Parkinson's disease. Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading to Parkinson's disease.
引用
收藏
页码:259 / 263
页数:5
相关论文
共 50 条
  • [31] MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma
    O'Driscoll, L.
    Walsh, N.
    Larkin, A.
    Ballot, J.
    Ooi, W. S.
    Gullo, G.
    O'Connor, R.
    Clynes, M.
    Crown, J.
    Kennedy, S.
    ANTICANCER RESEARCH, 2007, 27 (4B) : 2115 - 2120
  • [33] Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms
    Hemauer, Sarah J.
    Nanovskaya, Tatiana N.
    Abdel-Rahman, Sherif Z.
    Patrikeeva, Svetlana L.
    Hankins, Gary D. V.
    Ahmed, Mahmoud S.
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (06) : 921 - 925
  • [34] A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein
    Decleves, Xavier
    Chevillard, Sylvie
    Charpentier, Charlotte
    Vielh, Philippe
    Laplanche, Jean-Louis
    HUMAN MUTATION, 2000, 15 (05)
  • [35] Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein
    Bain, LJ
    LeBlanc, GA
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1996, 141 (01) : 288 - 298
  • [36] CLARIFICATION OF THE CHROMOSOMAL ASSIGNMENT OF THE HUMAN P-GLYCOPROTEIN MDR1 GENE (PGY1)
    TRENT, JM
    WITKOWSKI, CM
    RONINSON, IB
    LING, V
    CYTOGENETICS AND CELL GENETICS, 1987, 46 (1-4): : 705 - 705
  • [37] Cyclosporins:: Structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter
    Loor, F
    Tiberghien, FO
    Wenandy, T
    Didier, A
    Traber, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (21) : 4598 - 4612
  • [38] Inhibition of P-glycoprotein and reversal of multidrug resistance in mdr1 gene modified leukemia cells by mdr1 antisense RNA.
    Wang, W
    Chen, ZX
    Fu, JX
    Li, JY
    Bai, X
    Cen, JN
    Xue, YQ
    BLOOD, 2003, 102 (11) : 495B - 495B
  • [39] Modulation of MDR1 isoform of P-glycoprotein efflux transporter increases permeability of doxorubicin into the brain of the rat
    Giovannini, M. G.
    la Marca, G.
    Malvagia, S.
    Fratoni, V
    Cardellicchio, S.
    Guerrini, R.
    de Martino, M.
    Genitori, L.
    Sardi, I
    PROCEEDINGS OF THE 6TH EUROPEAN CONGRESS OF PHARMACOLOGY, 2013, : 115 - 117
  • [40] Pharmacogenomics of drug transporters: A new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1)
    Ishikawa, T
    Onishi, Y
    Hirano, H
    Oosumi, K
    Nagakura, M
    Tarui, S
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (07) : 939 - 948